These nanobodies have begun to fill an important gap in the tools needed to study PRL-3 function in normal physiology and cancer and have the potential to provide valuable insight into PRL-3 substrates, trafficking, structure, and inhibition. This evidence concerns the gene PTP4A3 and cancer.